Literature DB >> 8103797

Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney.

N Okamura1, M Hirai, Y Tanigawara, K Tanaka, M Yasuhara, K Ueda, T Komano, R Hori.   

Abstract

The mechanism of a renal tubular digoxin-cyclosporin A interaction was elucidated using a kidney epithelial cell line and the isolated perfused rat kidney. The cells expressed an excess amount of human P-glycoprotein on the apical membranes by transfection with MDR1 cDNA. Cyclosporin A inhibited the transepithelial transport of digoxin mediated by human P-glycoprotein; net basal-to-apical transport across the cell monolayer was 22.8, 21.2, 6.61 and 0.91 pmol/mg of protein/3 hr in the presence of 0, 1, 5 and 10 microM cyclosporin A, respectively. Cyclosporin A also reduced the renal tubular secretion of digoxin by the kidney. The ratio of fractional excretion/filtration fraction for digoxin was 2.88 +/- 0.71 (mean +/- S.D.) in the control, and this was decreased to 1.21 +/- 0.09 and 1.05 +/- 0.13 in the presence of 1 and 5 microM cyclosporin A, respectively. Because no signs of acute nephrotoxicity were observed, a direct effect of cyclosporin A accounted for the reduced secretion. On the other hand, digoxin did not affect cyclosporin A transport by P-glycoprotein. These findings indicate that serum concentrations of digoxin in patients should be carefully monitored when administered concurrently with cyclosporin A. The present transepithelial transport system using the transfectant cells is a simple and useful screening system for predicting drug interactions that can occur in a clinical situation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103797

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 2.  Measurement of renal function during drug development.

Authors:  D Craig Brater
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 3.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Authors:  U Mayer; E Wagenaar; J H Beijnen; J W Smit; D K Meijer; J van Asperen; P Borst; A H Schinkel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 5.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Drug exsorption from blood into the gastrointestinal tract.

Authors:  K Arimori; M Nakano
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 7.  Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

Authors:  David S Small; Nagy A Farid; Christopher D Payne; Christopher S Konkoy; Joseph A Jakubowski; Kenneth J Winters; Daniel E Salazar
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

8.  The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects.

Authors:  C Weber; L Banken; H Birnboeck; S Nave; R Schulz
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

9.  Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 10.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.